関連する実験動画

Updated: Jan 8, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

SGLT2阻害薬の2型糖尿病患者における腫瘍発生リスクへの影響：レトロスペクティブコホート研究

Yuzhe Wang¹, Yusen Ding², XiangLong Yan³

¹Special Needs Ward 1, Qingdao Endocrine and Diabetes Hospital, Shandong, 266011, People's Republic of China.

Diabetes, metabolic syndrome and obesity : targets and therapy

|December 22, 2025

要旨

Aim:

To assess the association between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and the risk of tumor development and survival outcomes in patients with type 2 diabetes.

Methods:

This retrospective cohort study included 350 patients with type 2 diabetes treated at our institution between January 2021 and January 2025. Patients were categorized into an observation group (n = 189) receiving SGLT2 inhibitors and a control group (n = 161) treated with other antidiabetic medications. Clinical characteristics, glycemic control, cumulative drug exposure, and tumor incidence (lung, colorectal, prostate, breast, bladder, and hepatic cancers) were analyzed. Kaplan-Meier methods were used to evaluate cancer incidence and mortality outcomes.

Results:

Overall tumor incidence was significantly lower in the SGLT2 inhibitor group than in the control group (P < 0.001), mainly due to reduced lung (P = 0.018) and ovarian cancers (P = 0.017). Smoking, alcohol consumption, and poor glycemic control were associated with higher overall and site-specific tumor risks. The SGLT2 inhibitor group showed better metabolic profiles, with lower FBG, HbA1c, LDL, TC, TG, and higher HDL levels (all P < 0.05), as well as improved renal function indicated by lower BUN and creatinine and higher eGFR (all P < 0.001). Kaplan-Meier analysis demonstrated significantly longer progression-free and overall survival in the SGLT2 inhibitor group (both P < 0.01).

Conclusion:

SGLT2 inhibitors reduced overall tumor risk, especially lung and ovarian cancers, and improved metabolic and survival outcomes in type 2 diabetes.

キーワード:

SGLT2阻害薬糖尿病治療薬腫瘍発生

さらに関連する動画

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

関連する概念動画

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...